logo-loader
RNS
Barclays PLC

FORM 38.5(b)- Osmotica Pharmaceuticals plc - AMENDMENT

--(BUSINESS WIRE)--LONDON

 

Ap27

FORM 38.5(b) - Amendment to Purchase

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

1. KEY INFORMATION

2. INTERESTS ANDSHORT POSITIONS

a. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

b. Interests and short positions in relevant securities of the company, otherthan the class dealt in (Note 2)

Ap28

3. DEALINGS (Note 3)

a. Purchases and sales

b. Derivatives transactions (other than options transactions)

i. Options transactions in respect of existing relevant securities

ii. Writing, selling, purchasingor varying

c. Exercising

d. Other dealings (including transactions in respect of new securities) (Note 3)

Ap29

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

 

BARCLAYS PLC

Source: BARCLAYS PLC

Name of exempt principal trader:

BARCLAYS CAPITAL INC

Company dealt in

OSMOTICA PHARMACEUTICALS PLC

Class of relevant security to which the 

ordinary sharesUS$0.01

dealings being disclosed relate 
Date of dealing

18 December 2020

Class of relevant security:ORD  
 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

320

0.00%

5,635

0.01%

  

 

 

 

 

(2)

Derivatives (other than options):

 

 

 

 

 

0

0.00%

0

0.00%

  

 

 

 

 

(3)

Options and agreements to

 

 

 

 

purchase/sell:

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

 

TOTAL:

320

0.00%

5,635

0.01%

 

 

 

 

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

Purchase/sale

Number of

Price per unit

 

securities

 

Purchase

100

5.7600   USD

Purchase

100

5.7500   USD

Purchase

140

5.7464   USD

Purchase

200

5.7750   USD

Purchase

427

5.7200   USD

Purchase

500

5.8280   USD

Purchase

6,054

5.8778   USD

Sale

5,719

5.7200   USD

Sale

7,094

5.8653   USD

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit

(Note 4)

 

 

 

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

 

 

 

 

 

 

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

 

 

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Is a Supplemental Form 38.5(b) attached? NO
Date of disclosure:

24 Dec 2020

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

Name of offeree/offeror with which connected

 

Nature of connection 
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read